Edinburgh HQ'd Resolution Therapeutics announced a £63.5M series B this month to advance its pro-regenerative macrophage therapy into further end-stage liver disease studies

blonca9
Oct 8, 2024
1 min read

CEO Amir Hefni describes how this autologous product is designed to work, the investments Resolution has made in its manufacturing process, what the money will enable the company to do, and more of what's next.

Recent Posts

See All

Cambridge, UK based Maxion Therapeutics raised a $72M series A in March to advance its KnotBody programs - which combine the benefits of knottins and antibodies and can target ion channels and GPCRs

ASGCT 2025: HuidaGene presented preclinical and early clinical data for its CRISPR Cas12 based program for DMD in a Presidential Symposium talk

ASGCT 2025: Dyno Therapeutics' CEO Eric Kelsic discusses the latest in capsids for CNS, ophthalmology, and neuromuscular conditions

Edinburgh HQ'd Resolution Therapeutics announced a £63.5M series B this month to advance its pro-regenerative macrophage therapy into further end-stage liver disease studies

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight